A Phase 3 interventional study of Nivolumab and Docetaxel/Paclitaxel in Esophageal Cancer, sponsored by Ono Pharmaceutical Co. Ltd. Completed at 89 sites in 8 countries. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2022-07-06.
Sponsored by Ono Pharmaceutical Co. Ltd · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing nivolumab in Esophageal Neoplasms — 4 open to participants now, 11 under way, none of them phase 3. Nivolumab · Esophageal Neoplasms.
Among the 18 studies testing nivolumab in Esophageal Neoplasms, this one is the 3rd largest by enrollment, is one of 2 that started in 2015, is the only one in phase 3, and was the 2nd registered.
1,874 studies on the registry are indexed under Esophageal Neoplasms; 502 are open to participants now.
Browse Esophageal Neoplasms studies →4 of the 18 studies testing nivolumab in Esophageal Neoplasms are open now, in 3 countries. Recruiting first, the newest first:
Diwakar Davar · Sites in United States
Ages 18+
National Taiwan University Hospital · Sites in Taiwan
Ages 18–85
National University Hospital, Singapore · Sites in Singapore
Ages 21–99
Mayo Clinic · Sites in United States
Ages 18+
By country, each count listing its studies:
Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 387 Esophageal Neoplasms studies recruiting now, 245 (63%) set no upper age limit and 75 (19%) stop at 75 or younger; 20 take children under 18; 36 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, nivolumab is the treatment under test here. Read study by study →
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 15 · Phase 3 1
First in 2015; this study’s year is marked. 2 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 419 is above the median of 58 across 1,347 interventional studies indexed under Esophageal Neoplasms.
Median enrollment 49 across the 18 interventional studies. Of the 5 that completed or were terminated, 1 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 18 have an industry lead sponsor. The 10 most frequent:
Ono Pharmaceutical Co. Ltd is the lead sponsor of 63 studies on the registry; 2 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.
Ono Pharmaceutical Co. Ltd has 1 study filed under Esophageal Neoplasms — fewer than ten, so there is no comparison to draw.
4 of the studies testing nivolumab in Esophageal Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04757363Memorial Sloan Kettering Cancer CenterA Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer | 2027-02 |
| NCT03044613Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer | 2027-03 |
| NCT06265285Mayo ClinicComparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program | 2027-05-01 |
| NCT07152678National Taiwan University HospitalBrachytherapy With Radiotherapy and Immunotherapy: Guided HDR Trial in Esophageal Squamous Cell Carcinoma | 2027-09 |
Add all 4 to your calendar (.ics) → With an account.
Among the 18 studies testing nivolumab in Esophageal Neoplasms, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of study is to evaluate the efficacy and safety of Nivolumab in unresectable advanced or recurrent esophageal cancer patients who have failed in standard chemotherapies.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Nivolumab 240 mg/body solution intravenously every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
Drug: Nivolumab
Docetaxel: Intravenously administered at a dose of 75 mg/m2 every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends OR Paclitaxel: Intravenously administered at a dose of 100 mg/m2 weekly for 6 weeks followed by 2-week drug holiday until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
Drug: Docetaxel/Paclitaxel
Drug pages: Docetaxel · Paclitaxel
Overall Survival
Time frame: ("Date of death from any cause" - "Date of randomization" + 1) / 30.4375. For subjects lost to follow-up and subjects who are alive at the time of data cutoff date, data will be censored at the time the subject was last confirmed to be alive.
Progression-free Survival
Please refer to the protocol, overall response and best overall response will be determined solely by imaging assessment according to the RECIST Guideline Version 1.1, and will not take into account any clinical/symptomatic progression. Evaluable imaging data will be overall response without an overall response of "Not Evaluable (NE)."
Time frame: ("Earlier date on which either the overall response was assessed as PD or the subject died of any cause" - "Date of randomization" + 1) / 30.4375.
Duration of Response
Please refer to the protocol, overall response and best overall response will be determined solely by imaging assessment according to the RECIST Guideline Version 1.1, and will not take into account any clinical/symptomatic progression. Evaluable imaging data will be overall response without an overall response of "Not Evaluable (NE)."
Time frame: ("Earlier date on which either the overall response was assessed as PD for the first time after confirmed response or the subject died of any cause" - "Date of first assessment of confirmed CR or PR" + 1) / 30.4375.
| Milestone | Nivolumab Arm | Active Comparator Arm (Docetaxel/Paclitaxel) |
|---|---|---|
| Started | 210 | 209 |
| Completed | 209 | 208 |
| Not completed | 1 | 1 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| months | Nivolumab Arm | Active Comparator Arm (Docetaxel/Paclitaxel) |
|---|---|---|
| Overall Survival | 10.9 (9.2 to 13.3) | 8.4 (7.2 to 9.9) |
Please refer to the protocol, overall response and best overall response will be determined solely by imaging assessment according to the RECIST Guideline Version 1.1, and will not take into account any clinical/symptomatic progression. Evaluable imaging data will be overall response without an overall response of "Not Evaluable (NE)."
| months | Nivolumab Arm | Active Comparator Arm (Docetaxel/Paclitaxel) |
|---|---|---|
| Progression-free Survival | 1.7 (1.5 to 2.7) | 3.4 (3.0 to 4.2) |
Please refer to the protocol, overall response and best overall response will be determined solely by imaging assessment according to the RECIST Guideline Version 1.1, and will not take into account any clinical/symptomatic progression. Evaluable imaging data will be overall response without an overall response of "Not Evaluable (NE)."
| months | Nivolumab Arm | Active Comparator Arm (Docetaxel/Paclitaxel) |
|---|---|---|
| Duration of Response | 6.9 (5.4 to 11.1) | 3.9 (2.8 to 4.2) |
Collected over Monitoring for any AEs will be continued until 28 days after the end of the treatment phase. In subjects who, at the time of initiation of the follow-up investigation, have any AE for which a causal relationship to the investigational product cannot be ruled out or which led to discontinuation, investigation of the AE will be continued until the event is judged not to require further follow-up. SAEs are to be collected during the treatment period and for 100 days following the last dose.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Nivolumab Arm | 7/209 (3.3%) | 68/209 (32.5%) | 185/209 (88.5%) |
| Active Comparator Arm (Docetaxel/Paclitaxel) | 5/208 (2.4%) | 77/208 (37%) | 204/208 (98.1%) |
| Event | Nivolumab Arm | Active Comparator Arm (Docetaxel/Paclitaxel) |
|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 0/209 | 16/208 |
| PneumoniaInfections and infestations | 10/209 | 13/208 |
| Decreased appetiteMetabolism and nutrition disorders | 3/209 | 6/208 |
| PyrexiaGeneral disorders | 6/209 | 1/208 |
| Lung infectionInfections and infestations | 1/209 | 5/208 |
| HypercalcaemiaMetabolism and nutrition disorders | 4/209 | 1/208 |
| Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders | 4/209 | 3/208 |
| Neutrophil count decreasedInvestigations | 0/209 | 3/208 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 1/209 | 3/208 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 3/209 | 3/208 |
| Event | Nivolumab Arm | Active Comparator Arm (Docetaxel/Paclitaxel) |
|---|---|---|
| AlopeciaSkin and subcutaneous tissue disorders | 3/209 | 100/208 |
| Neutrophil count decreasedInvestigations | 3/209 | 76/208 |
| White blood cell count decreasedInvestigations | 2/209 | 72/208 |
| Decreased appetiteMetabolism and nutrition disorders | 40/209 | 68/208 |
| AnaemiaBlood and lymphatic system disorders | 24/209 | 61/208 |
| FatigueGeneral disorders | 19/209 | 52/208 |
| MalaiseGeneral disorders | 12/209 | 49/208 |
| Peripheral sensory neuropathyNervous system disorders | 1/209 | 48/208 |
| NeutropeniaBlood and lymphatic system disorders | 1/209 | 40/208 |
| ConstipationGastrointestinal disorders | 35/209 | 40/208 |
| Age, Categorical(Participants) | Nivolumab Arm | Active Comparator Arm (Docetaxel/Paclitaxel) | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 112 | 85 | 197 |
| >=65 years | 98 | 124 | 222 |
| Age, Continuous(years) | Nivolumab Arm | Active Comparator Arm (Docetaxel/Paclitaxel) | Total |
|---|---|---|---|
| Mean | 64 (57 to 69) | 67 (57 to 72) | 65 (57 to 71) |
| Sex: Female, Male(Participants) | Nivolumab Arm | Active Comparator Arm (Docetaxel/Paclitaxel) | Total |
|---|---|---|---|
| Female | 31 | 24 | 55 |
| Male | 179 | 185 | 364 |
| Race (NIH/OMB)(Participants) | Nivolumab Arm | Active Comparator Arm (Docetaxel/Paclitaxel) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 201 | 200 | 401 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 9 | 9 | 18 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Nivolumab Arm | Active Comparator Arm (Docetaxel/Paclitaxel) | Total |
|---|---|---|---|
| Asian | 201 | 200 | 401 |
| White | 9 | 9 | 18 |
| ECOG performance status(Participants) | Nivolumab Arm | Active Comparator Arm (Docetaxel/Paclitaxel) | Total |
|---|---|---|---|
| 0 | 101 | 107 | 208 |
| 1 | 109 | 102 | 211 |
| Disease stage : TNM classification(Participants) | Nivolumab Arm | Active Comparator Arm (Docetaxel/Paclitaxel) | Total |
|---|---|---|---|
| II - III | 8 | 13 | 21 |
| IV | 94 | 100 | 194 |
| unknown | 5 | 7 | 12 |
| Previous therapies(Participants) | Nivolumab Arm | Active Comparator Arm (Docetaxel/Paclitaxel) | Total |
|---|---|---|---|
| Surgery | 111 | 94 | 205 |
| Radiothrapy | 153 | 142 | 295 |
| Systemic anticancer therapy | 210 | 208 | 418 |
4 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Dec 2015 to primary completion in Oct 2020, 58 months.
Results were first posted in Jan 2022, 1 year 2 months after primary completion.
Of 57 phase 3 interventional studies under Esophageal Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 113. This study's 58 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nivolumab